Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AC0058TA · 1 trial · 1 indication
Frequency and severity of AEs and serious AEs
| Arm | Type | Description |
|---|---|---|
| AC0058TA | EXPERIMENTAL | Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA |
| Placebo capsules | PLACEBO_COMPARATOR | Drug: Placebo capsules |
| Name | Type | Description |
|---|---|---|
| AC0058TA | DRUG | 50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA |
| Placebo capsules | DRUG | Placebo capsules |
Inclusion Criteria: * Male or female, of any ethnic origin, age ≥18 and ≤65 years of age; * BMI ≥18.5 and ≤32.0 kg/m2; * Medical history without major pathology and determined to be in good health with no clinically significant findings as assessed by the Investigator; * All clinical laboratory tes...
AC0058TA is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, meaning it has not been approved for any medical use. The drug is being evaluated for safety and tolerability in a clinical trial setting.
AC0058TA is being developed by Scilex Holding Company, a biopharmaceutical company. Scilex is publicly traded under the ticker symbol SCLX. The company is conducting clinical research on this investigational drug candidate.
AC0058TA is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
AC0058TA has one completed clinical trial, identified as NCT02847325. This Phase 1 study, titled "Study of AC0058TA in Healthy Male and Female Subjects," was conducted in the United States and enrolled 56 participants. The trial was randomized, double-blind, and placebo-controlled.
AC0058TA is the primary name for this investigational drug candidate. No alternative names have been reported for this compound in the available clinical trial information. It is being studied under this name in its Phase 1 clinical development.